How A Drug Shortage Hiked Relapse Risks For Lymphoma Patients : Shots - Health News The short supply of a key drug to treat lymphoma forced doctors to switch to another medicine. Now researchers have documented that the fallback drug wasn't as good a choice as many doctors thought.
NPR logo

How A Drug Shortage Hiked Relapse Risks For Lymphoma Patients

  • Download
  • <iframe src="" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript
How A Drug Shortage Hiked Relapse Risks For Lymphoma Patients

How A Drug Shortage Hiked Relapse Risks For Lymphoma Patients

  • Download
  • <iframe src="" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript


From NPR News, this is ALL THINGS CONSIDERED. I'm Robert Siegel.

Doctors have been struggling for years to cope with drug shortages. They worry that shortages can hurt patients. Well, now, a research has documented the first direct evidence that a drug scarcity harmed patients. As NPR's Rob Stein reports, the shortage affected children, teenagers and young adults who are being treated for lymphoma.

ROB STEIN, BYLINE: Katie Alonzo was stunned when doctors told her they had run out of a drug her 10-year-old daughter, Abby, was taking to fight lymphoma.

KATIE ALONZO: When a doctor says, this is what you need to take, and then all of a sudden, somebody tells you, well, that is what you need to take, but this isn't available so we're going to try this instead, it's very scary.

STEIN: The company that sells the drug her daughter had been taking had run into problems producing it. It's the kind of thing that's been causing lots of shortages. These days, drugs are often made only by one company. So when that company has to halt production for some reason, it quickly creates a shortage. But doctors assured Abby's mom that the chemo they are giving Abby instead would work just as well.

ALONZO: This was just a stumbling block and we got over it. And I was told that there was nothing wrong with taking this other medication. It'll be fine. And we did and we just kept on from there.

STEIN: But privately, Abby's doctors were concerned about whether the fallback drug would work as well. And they knew lots of doctors had been making similar tough choices every day. Monika Metzger at St. Jude Hospital in Memphis is one of Abby Alonzo's doctors.

MONIKA METZGER: Up until now, there was a lot of speculation as to these drug shortages, and doctors were worried about what this could mean to their patients. But until now, there was no evidence that it actually caused any harm.

STEIN: So Metzger and her colleagues decided to study their lymphoma patients to see what happened. In this week's issue of the New England Journal of Medicine, they're reporting that their fears were true. Those who got the other drug were significantly more likely to suffer a relapse.

METZGER: Unfortunately, we were the first ones to actually prove that, yes, indeed, there was harm done.

STEIN: None of the patients died. But they were forced to undergo another grueling round of chemotherapy, more radiation and procedures to replace their bone marrow.

METZGER: It's very toxic. The chemotherapy's incredibly intense. Patients are at a lot of risk of serious complications.

STEIN: Complications including life-threatening infections and an increased risk of developing other cancers later in life because of the additional chemo. Metzger says, one of the most frightening things about her case is that there was every reason to assume that the substitute drug was just as good.

METZGER: This was quite a scary example that even where you think you have the best situation, you cannot rely on that substitution.

STEIN: The big worry is that this lymphoma case is far from unique. Michael Lin at Stanford helped do the new study.

MICHAEL LIN: This is only the tip of the iceberg because this is only dealing with the anti-cancer drugs. We have heard plenty of horror stories because of shortages of antibiotics and anesthetic drugs as well.

STEIN: Abby Alonzo, the little girl we heard about at the beginning, was one of the casualties of the drug shortages. Her mother says Abby had a relapse soon after being switched to the substitute drug.

ALONZO: That was really horrible. She was in the hospital and she was in isolation. It was just - it was real lonely. It was really sad. It was painful. It was - I mean, she was just miserable. She was miserable.

STEIN: Abby's now 13. All the cancer and treatment damaged her lungs, so it's hard for her to play soccer. But there's no sign of any cancer. Her mom hadn't even make the connection between the relapse of the drug shortage until a couple of weeks ago when the doctors told her about what they had discovered.

ALONZO: The idea that a child might relapse for no other reason except the unavailability of drugs that kids need in order to get rid of their cancer is - I mean, it's just insane. It's just sad. It's just sad. It makes me angry. You know, I wish there was a way to prevent it, I guess.

STEIN: Federal officials have been trying to alleviate the shortages. Companies are now required to alert the FDA when a shortage is coming so the agency can try to find alternative sources, and the number of new shortages dropped this year for the first time in five years. The drug Abby needed just became available again. But about 280 drugs remain scarce, making it clear more needs to be done. Rob Stein, NPR News.

Copyright © 2012 NPR. All rights reserved. Visit our website terms of use and permissions pages at for further information.

NPR transcripts are created on a rush deadline by Verb8tm, Inc., an NPR contractor, and produced using a proprietary transcription process developed with NPR. This text may not be in its final form and may be updated or revised in the future. Accuracy and availability may vary. The authoritative record of NPR’s programming is the audio record.